Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 6/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5555057 | 0.91 | CCR1 (0.60) | CCR1CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL3487314 | 0.90 | CCR1 (0.44) | CCR1CHRM2CHRM1CHRM3SMYD3 | |
| SCHEMBL15130431 | 0.89 | CHRM5 (0.48) | CCR1CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL15191011 | 0.89 | CHRM5 (0.48) | CCR1CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL4119272 | 0.87 | CHRM5 (0.52) | CCR1CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL4119281 | 0.87 | CHRM5 (0.52) | CCR1CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL14760896 | 0.85 | CHRM2 (0.48) | CCR1CHRM2CHRM1CHRM3CYP3A4 | |
| SCHEMBL27224933 | 0.84 | CHRM3 (0.49) | CCR1CHRM2CHRM1CHRM3SMYD3 | |
| SCHEMBL27232352 | 0.84 | CHRM3 (0.49) | CCR1CHRM2CHRM1CHRM3SMYD3 | |
| SCHEMBL6118868 | 0.84 | PDE7A (0.47) | CCR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103097352-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2013-05-08 | — | — | CN | disclosed |
| CN-102947285-A | Sulfonamide derivatives as BCL-2-selective apoptosis inducers for the treatment of cancer and immune diseases | ABBOTT LAB | 2013-02-27 | — | — | CN | disclosed |
| US-20080200460-A1 | Chemical Compounds | BROWN DEARG | 2008-08-21 | — | — | US | disclosed |
| EP-1833792-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS CCR5 MODULATORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006067385-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200460-A1 | Chemical Compounds | CCR5, CXCR4, CXCR5 | CCR1 19/4885CHRM2 158/4885CHRM1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.